| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: a pilot study KA Sieradzan, SH Fox, M Hill, JPR Dick, AR Crossman, JM Brotchie Neurology 57 (11), 2108-2111, 2001 | 414 | 2001 |
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease V Di Marzo, MP Hill, T Bisogno, AR Crossman, JM Brotchie The FASEB Journal 14 (10), 1432-1438, 2000 | 390 | 2000 |
| A role for endocannabinoids in the generation of parkinsonism and levodopa‐induced dyskinesia in MPTP‐lesioned non‐human primate models of Parkinson's disease M van der Stelt, SH Fox, M Hill, AR Crossman, S Petrosino, V Di Marzo, ... The FASEB journal 19 (9), 1140-1142, 2005 | 219 | 2005 |
| Fipamezole (JP‐1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa‐induced dyskinesia in the MPTP‐lesioned primate model of Parkinson … JM Savola, M Hill, M Engstrom, H Merivuori, S Wurster, SG McGuire, ... Movement disorders: official journal of the Movement Disorder Society 18 (8 …, 2003 | 192 | 2003 |
| Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's disease SH Fox, B Henry, M Hill, A Crossman, J Brotchie Movement disorders: official journal of the Movement Disorder Society 17 (6 …, 2002 | 187 | 2002 |
| Sleep disorders in Parkinson's disease: the contribution of the MPTP non-human primate model Q Barraud, V Lambrecq, C Forni, S McGuire, M Hill, B Bioulac, E Balzamo, ... Experimental neurology 219 (2), 574-582, 2009 | 156 | 2009 |
| Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease JE Nash, SH Fox, B Henry, MP Hill, D Peggs, S McGuire, Y Maneuf, ... Experimental neurology 165 (1), 136-142, 2000 | 150 | 2000 |
| Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat JE Nash, MP Hill, JM Brotchie Experimental neurology 155 (1), 42-48, 1999 | 111 | 1999 |
| Neural mechanisms underlying peak‐dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha2 adrenoceptor … SH Fox, B Henry, MP Hill, D Peggs, AR Crossman, JM Brotchie Movement disorders: official journal of the Movement Disorder Society 16 (4 …, 2001 | 106 | 2001 |
| Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials W Meissner, MP Hill, F Tison, CE Gross, E Bezard Trends in pharmacological sciences 25 (5), 249-253, 2004 | 102 | 2004 |
| Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes SJ East, MP Hill, JM Brotchie European journal of pharmacology 277 (1), 117-121, 1995 | 99 | 1995 |
| Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease MP Hill, P Ravenscroft, E Bezard, AR Crossman, JM Brotchie, A Michel, ... Journal of Pharmacology and Experimental Therapeutics 310 (1), 386-394, 2004 | 87 | 2004 |
| Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque E Bezard, MP Hill, AR Crossman, JM Brotchie, A Michel, R Grimée, ... European journal of pharmacology 485 (1-3), 159-164, 2004 | 85 | 2004 |
| The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures MJ Millan, JJ Buccafusco, F Loiseau, DJG Watson, E Decamp, KCF Fone, ... International Journal of Neuropsychopharmacology 13 (8), 1035-1051, 2010 | 83 | 2010 |
| Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit KL Eskow Jaunarajs, DG Standaert, TX Viegas, MD Bentley, Z Fang, ... Movement Disorders 28 (12), 1675-1682, 2013 | 69 | 2013 |
| Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease O Zachrisson, M Zhao, A Andersson, K Dannaeus, J Häggblad, R Isacson, ... Journal of Parkinson's disease 1 (1), 49-63, 2011 | 68 | 2011 |
| Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L‐dopa and ropinirole in the MPTP‐lesioned marmoset MP Hill, E Bezard, SG McGuire, AR Crossman, JM Brotchie, A Michel, ... Movement disorders: official journal of the Movement Disorder Society 18 (11 …, 2003 | 67 | 2003 |
| Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys PO Fernagut, Q Li, S Dovero, P Chan, T Wu, P Ravenscroft, M Hill, Z Chen, ... PLoS One 5 (11), e14053, 2010 | 65 | 2010 |
| Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease C Kobylecki, MP Hill, AR Crossman, P Ravenscroft Movement disorders 26 (13), 2354-2363, 2011 | 62 | 2011 |
| Modulation of glutamate release by a κ-opioid receptor agonist in rodent and primate striatum MP Hill, JM Brotchie European journal of pharmacology 281 (1), R1-R2, 1995 | 58 | 1995 |
